

## PRESS RELEASE

**innate** pharma

---

### **R&D UPDATE ON APRIL 10, 2014 IN NEW YORK**

- *Innate Pharma will update investors and analysts on its pipeline and strategy*
- *The Company will present the clinical development plan of IPH2201 NKG2A checkpoint inhibitor, expected to start Phase II in 2014*

**Marseille, March 17, 2014**


---

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Company will host a Research and Development Update on April 10, 2014, in New York, from 8am to 1pm.

At this R&D Update, Innate Pharma's management team will review and discuss with attendees Innate Pharma's pipeline and strategy. The Company will present the clinical development plan for IPH2201, a first-in-class NKG2A checkpoint inhibitor, which Phase II in oncology is expected to start in 2014.

Attendance is by invitation only and subject to room capacity.

**The R&D Update will be live webcasted and also available after the event at the following link: <http://psav.rampard.com/20140410/>**



## PRESS RELEASE

**innate** pharma

---

### **About Innate Pharma:**

Innate Pharma S.A. is a biopharmaceutical company conducting research and development of innovative immunotherapy drug candidates for cancer and inflammatory diseases.

The company specializes in the development of first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Three product-candidates resulting from the company's research platform are currently being tested in clinical trials, two of which by partners Bristol-Myers Squibb and Novo Nordisk A/S.

Listed on Euronext-Paris, Innate Pharma is based in Marseilles, France, and had 84 employees as at December 31, 2013.

Learn more about Innate Pharma at [www.innate-pharma.com](http://www.innate-pharma.com).

### **Practical Information about Innate Pharma shares:**

<b>ISIN code</b>	FR0010331421
<b>Ticker code</b>	IPH

### **Disclaimer:**

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website ([www.amf-france.org](http://www.amf-france.org)) or on Innate Pharma's website ([www.innate-pharma.com](http://www.innate-pharma.com)).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

### **For additional information, please contact:**

#### **Innate Pharma**

Laure-Hélène Mercier  
Director, Investor Relations  
Phone: +33 (0)4 30 30 30 87  
[investors@innate-pharma.com](mailto:investors@innate-pharma.com)

#### **ATCG Press**

Marielle Bricman  
Mob.: +33 (0)6 26 94 18 53  
[mb@atcg-partners.com](mailto:mb@atcg-partners.com)